Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Monday 18 November, 2019

Almea 2 Sg Portfolio

AbbVie Inc. 38.5b

RNS Number : 7481T
Almea 2 Segregated Portfolio Co.
18 November 2019
 

Ap27

 

 

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED 
INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 

1.          KEY INFORMATION

 

Name of exempt principal trader

Almea 2 Segregated Portfolio Company

Company dealt in

AbbVie Inc.

Class of relevant security to which the dealings being disclosed relate (Note 1)

Common stock

Date of dealing

15 November 2019

 

2.          INTERESTS AND SHORT POSITIONS

 

(a)         Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

 

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

   20,956                   0.00%

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

    20,956                   0.00%

             

 

 

(b)         Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

 

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

             

 

Ap28

 

 

3.       DEALINGS (Note 3)

 

(a)      Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

(USD)

Purchase

 

Sale

 

676

 

1,430

3,293

88.8100

 

88.6200

88.7300

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 5)

Number of relevant securities

(Note 6)

Price per unit

(Note 4)

 

 

 

 

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 4)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 4)

 

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 3)

 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

 

 

 

 

Ap29

 

4.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities 
under any option referred to on this form or relating to the voting rights or future acquisition 
or disposal of any relevant securities to which any derivative referred to on this form is referenced. 
If none, this should be stated.

 

 

 

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached? (Note 8)                    NO

 

 

Date of disclosure

18 November 2019

Contact name

Alwyn Basch

Telephone number

020 7742 7407

Name of offeree/offeror with which connected

Allergan plc

Nature of connection (Note 9)

Financial Advisor to Allergan plc

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEKMMMMGRZGLZM

a d v e r t i s e m e n t